Compare Commvault Systems Inc (CVLT) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Commvault (CVLT) trades at $148.65, down 1.28% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.28 exceeding the $1.09 estimate, though Q3 2025 missed expectations. Revenue reached $995.62 million in 2025, with a net income margin of 5.97%. However, valuation ratios are elevated, including a P/E of 94.03 and P/B of 821.14, indicating high growth expectations. Recent news highlights multiple class-action lawsuits with a July 17, 2026 deadline, adding legal overhangs.

The outlook for CVLT is mixed, with solid profitability and analyst buy ratings (54.55% consensus) supporting upside to the $155.00 high target, but risks from the lawsuits and rich valuations could pressure the stock. Investors should weigh robust cash flow growth in 2026 against potential legal and competitive headwinds in the data protection sector.

INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.

The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.